Search Result

Results for "

bile duct

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (3) 5-HT Receptor (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Cholecystokinin Receptor (3) Endogenous Metabolite (1) FXR (1) Histamine Receptor (3) Integrin (2) Interleukin Related (1) Isotope-Labeled Compounds (3) Proteasome (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Endocrinology (3) Inflammation/Immunology (4) Metabolic Disease (12) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109120

Odevixibat 3 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-B1557

Betazole 1 Publications Verification Ametazole	Histamine Receptor	Metabolic Disease
Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .

HY-N1427

Glycodeoxycholate Sodium Sodium glycyldeoxycholate	Endogenous Metabolite	Metabolic Disease
Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .

HY-A0190

Ceruletide Maximum Cited Publications 76 Publications Verification Caerulein; Cerulein; FI-6934	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-B1557A

Betazole dihydrochloride Ametazole dihydrochloride	Histamine Receptor	Metabolic Disease
Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .

HY-B1557R

Betazole (Standard)	Histamine Receptor	Metabolic Disease
Betazole (Standard) is the analytical standard of Betazole. This product is intended for research and analytical applications. Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .

HY-158722

Caerulein acetate	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-N10810

Gentioflavin	Others	Others
Gentioflavin is an alkaloid. Gentioflavin can be isolated from the root of Long Dan (G. scabra), a traditional substance against liver or bile duct disease .

HY-136750

Z-LLY-FMK Calpain Inhibitor IV	Apoptosis Proteasome	Cancer
Z-LLY-FMK (Calpain Inhibitor IV) is a calpain inhibitor, involved in apoptosis of many cell systems. Z-LLY-FMK inhibits the intestine apoptosis after common bile duct ligation .

HY-A0190R

Ceruletide (Standard)	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide (Standard) is the analytical standard of Ceruletide. This product is intended for research and analytical applications. Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-120396

LY 293284	5-HT Receptor	Neurological Disease
LY 293284 is a potent and selective 5-HT1A receptor agonist. LY 293284 results in a significant drop in core temperature and consumes more food in cholestasis rat induced by bile duct resection .

HY-W747072

3-Sulfo-taurocholic Acid Disodium Salt 3-Sulfocholyl Taurine; TCA3S	Others	Metabolic Disease
3-Sulfo-taurocholic Acid Disodium Salt (3-Sulfocholyl Taurine; TCA3S) is a metabolite of the conjugated bile acid taurocholic acid. Plasma levels of 3-Sulfo-taurocholic Acid Disodium Salt are elevated in wild-type and Sortilin 1 (Sort1) knockout mice at 6 hours following bile duct ligation (BDL) and are further elevated in Sort1 knockout mice at 24 hours post-BDL.

HY-B0149S3

Tranexamic acid-13C2,15N Cyclocapron-¹³C₂,¹⁵N	Isotope-Labeled Compounds	Inflammation/Immunology
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-139562

BMS-986318	FXR	Metabolic Disease
BMS-986318 is a potent nonbile acid FXR agonist with EC₅₀s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis .

HY-137561A

Bexotegrast hydrochloride PLN-74809 hydrochloride	Integrin Others	Inflammation/Immunology
Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .

HY-164202

ORM-5029	Antibody-Drug Conjugates (ADCs)	Cancer
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer .

HY-169004

CBT-295	TGF-beta/Smad Interleukin Related	Neurological Disease Inflammation/Immunology
CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .

HY-101473

EMD527040	Integrin	Inflammation/Immunology
EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research .

Ceruletide 75+ Cited Publications Caerulein; Cerulein; FI-6934	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

Caerulein acetate	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

Ceruletide (Standard)	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide (Standard) is the analytical standard of Ceruletide. This product is intended for research and analytical applications. Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1427

Glycodeoxycholate Sodium Sodium glycyldeoxycholate	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .

HY-A0190

Ceruletide 75+ Cited Publications Caerulein; Cerulein; FI-6934	Cardiovascular Disease Alkaloids Structural Classification Animals Classification of Application Fields Source classification Disease Research Fields Endocrinology Indole Alkaloids	Cholecystokinin Receptor
Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-N10810

Gentioflavin	Structural Classification Gentiana scabra Bunge Source classification Magnoliaceae Gentianaceae Plants Steroids	Others
Gentioflavin is an alkaloid. Gentioflavin can be isolated from the root of Long Dan (G. scabra), a traditional substance against liver or bile duct disease .

HY-A0190R

Ceruletide (Standard)	Alkaloids Structural Classification Animals Source classification Indole Alkaloids	Cholecystokinin Receptor
Ceruletide (Standard) is the analytical standard of Ceruletide. This product is intended for research and analytical applications. Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

Cat. No.	Product Name	Chemical Structure

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal *apical sodium-dependent bile* acid transporter (ASBT*) inhibitor. Odevixibat decreases cholestatic liver and bile* duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-B0149S3

Tranexamic acid-13C2,15N
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

bile duct

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products